Hemab Therapeutics (COAG) Stock Forecast & Price Target
Score
Hemab Therapeutics Holdings, Inc. Common Stock price target
| COAG | |
|---|---|
| Low | $36.00 |
| Average | $51.40 |
| High | $64.00 |
| Upside vs current price | +25.8% |
The average target of $51.40 is +25.8% versus the current COAG price of $40.86.
Hemab Therapeutics Holdings, Inc. Common Stock analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 0 |
| Buy | 3 |
| Hold | 0 |
| Sell | 0 |
| Strong sell | 0 |
| Consensus | Buy |
3 analysts cover COAG.
Hemab Therapeutics Holdings, Inc. Common Stock EPS and revenue estimates
COAG shows the next fiscal years with at least three analysts: 2026 EPS $-3.05, 2027 EPS $-2.47. A thinner year is left off this table.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $-3.05 | — |
| 2027 | $-2.47 | — |
Is Hemab Therapeutics Holdings, Inc. Common Stock a buy or sell?
Of the 3 analysts covering Hemab Therapeutics Holdings, Inc. Common Stock, 3 rate it a buy (0 strong buy and 3 buy), 0 rate it a hold, and 0 rate it a sell (0 sell and 0 strong sell).
The COAG consensus label is Buy, beside 3 buy-side ratings and 0 sell-side ratings.
The average target of $51.40 implies +25.8% versus the current price of $40.86.
Those 3 ratings on COAG are a headcount, and the label on file is Buy.
Reading the Hemab Therapeutics Holdings, Inc. Common Stock forecast
The COAG target range is wide: $36.00 at the low end, $51.40 in the middle, and $64.00 at the top.
Set next to the $40.86 COAG quote, that average is +25.8%.
Ratings on the Hemab Therapeutics Holdings, Inc. Common Stock cluster: 3 of 3 analysts are on the buy side, 0 are at hold, and 0 are on the sell side, and the published consensus is Buy.
The COAG EPS path from 2026 ($-3.05) to 2027 ($-2.47) is rising.
Only 3 analysts cover COAG, so the average rests on a short list.
Hemab Therapeutics Holdings, Inc. Common Stock forecast questions
What is the COAG price target?
The published range for COAG is $36.00 to $64.00, with an average of $51.40. That average is +25.8% versus the current price of $40.86.
Is Hemab Therapeutics Holdings, Inc. Common Stock a buy or sell?
Of the 3 analysts covering Hemab Therapeutics Holdings, Inc. Common Stock, 3 rate it a buy, 0 rate it a hold, and 0 rate it a sell. The consensus is Buy, and the COAG headcount is 3 buy, 0 hold, and 0 sell.
What is the EPS estimate for Hemab Therapeutics Holdings, Inc. Common Stock?
Analyst EPS estimates for Hemab Therapeutics Holdings, Inc. Common Stock: 2026 $-3.05, 2027 $-2.47.
What is the revenue estimate for Hemab Therapeutics Holdings, Inc. Common Stock?
No revenue estimate with at least 3 analysts is on file for Hemab Therapeutics Holdings, Inc. Common Stock.
How many analysts cover COAG?
3 analysts cover COAG. Their consensus on COAG is Buy, across those 3.